These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20408829)

  • 1. Bell's palsy during etanercept treatment caused by neuroborreliosis.
    Molin S; Ruzicka T; Prinz JC
    Br J Dermatol; 2010 Jul; 163(1):228-30. PubMed ID: 20408829
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept.
    Yamauchi PS; Lowe NJ; Gindi V
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S121-2. PubMed ID: 16488323
    [No Abstract]   [Full Text] [Related]  

  • 3. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
    Yamauchi PS; Lowe NJ
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
    [No Abstract]   [Full Text] [Related]  

  • 4. Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept.
    Cusano F; Iannazzone SS; Riccio G; Piccirillo F
    Eur J Dermatol; 2010; 20(4):520. PubMed ID: 20403800
    [No Abstract]   [Full Text] [Related]  

  • 5. Adolescent plaque psoriasis: our experience using etanercept.
    Ruiz-Villaverde R; Sánchez-Cano D; Abalos-Medina G
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):976-7. PubMed ID: 19207668
    [No Abstract]   [Full Text] [Related]  

  • 6. Ability to develop rhus allergic contact dermatitis in a patient with psoriasis receiving etanercept.
    Myers W; Newman M; Katz B; Gottlieb AB
    J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S127-8. PubMed ID: 17052536
    [No Abstract]   [Full Text] [Related]  

  • 7. Etanercept for the treatment of severe childhood psoriasis.
    Papoutsaki M; Costanzo A; Mazzotta A; Gramiccia T; Soda R; Chimenti S
    Br J Dermatol; 2006 Jan; 154(1):181-3. PubMed ID: 16403117
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical characteristics and cerebrospinal fluid parameters in patients with peripheral facial palsy caused by Lyme neuroborreliosis compared with facial palsy of unknown origin (Bell's palsy).
    Bremell D; Hagberg L
    BMC Infect Dis; 2011 Aug; 11():215. PubMed ID: 21831262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe nail psoriasis with etanercept.
    Coelho JD; Diamantino F; Lestre S; Ferreira AM
    Indian J Dermatol Venereol Leprol; 2011; 77(1):72-4. PubMed ID: 21220889
    [No Abstract]   [Full Text] [Related]  

  • 10. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant.
    Collazo MH; González JR; Torres EA
    P R Health Sci J; 2008 Dec; 27(4):346-7. PubMed ID: 19069362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept for the treatment of psoriasis.
    Bissonnette R
    Skin Therapy Lett; 2006 Feb; 11(1):1-4. PubMed ID: 16485060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept in psoriasis treatment.
    Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data.
    Paradisi A; Caldarola G; Capizzi R; Siciliano M; Annichiarico E; Vecchio FM; Amerio PL; De Simone C
    J Am Acad Dermatol; 2010 Jun; 62(6):1067-9. PubMed ID: 20466184
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
    Farnsworth NN; George SJ; Hsu S
    Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
    [No Abstract]   [Full Text] [Related]  

  • 15. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
    Antoniou C; Dessinioti C; Stratigos A; Avgerinou G; Stavropoulos P; Katsambas A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):979-82. PubMed ID: 19470056
    [No Abstract]   [Full Text] [Related]  

  • 16. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection.
    Rokhsar C; Rabhan N; Cohen SR
    J Am Acad Dermatol; 2006 Feb; 54(2):361-2. PubMed ID: 16443079
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection.
    Alcaide AJ; Barrera MV; Habicheyn S; López N; Mendiola MV; Herrera E
    J Eur Acad Dermatol Venereol; 2008 Dec; 22(12):1514-6. PubMed ID: 18355196
    [No Abstract]   [Full Text] [Related]  

  • 18. Disseminated superficial porokeratosis secondary to immunosuppression induced by etanercept for extensive psoriasis.
    Stewart L; Howat A; Coulson I
    Arch Dermatol; 2010 Oct; 146(10):1193-4. PubMed ID: 20956674
    [No Abstract]   [Full Text] [Related]  

  • 19. [Patient education. Information letter on treatment of psoriasis with etanercept (Enbrel)].
    Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011
    Ann Dermatol Venereol; 2011 Dec; 138(12):871-3. PubMed ID: 22137635
    [No Abstract]   [Full Text] [Related]  

  • 20. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.